Off-label use of recombinant activated factor VII in intractable haemorrhage after cardiovascular surgery: An observational study of practices in 23 French cardiac centres (2005-7)

European Journal of Cardio-thoracic Surgery

Volumn 40, Issue 6, 2011, Pages 1320-1327

  Hacquard, Marie ^a,b,c   Durand, Marion ^a,b,c   Lecompte, Thomas ^a,b,c   Boini, Stéphanie ^a,b,d   Briançon, Serge ^a,b,d   Carteaux, Jean Pierre ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ DE LORRAINE   (France)

^c Nancy Hospital   (France)

^d INSERM CIC EC CIE6 ^*  (France)

Author keywords

Cardiac surgery; Coagulation; Haemorrhage; Registries; RFVIIa

Indexed keywords

FIBRINOGEN; FRESH FROZEN PLASMA; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBOCYTE CONCENTRATE;

ADOLESCENT; ADULT; AGED; ARTICLE; BLEEDING; BLOOD TRANSFUSION; CARDIOVASCULAR SURGERY; ERYTHROCYTE TRANSFUSION; FEMALE; HEART ASSIST DEVICE; HUMAN; INTENSIVE CARE UNIT; INTRACTABLE HEMORRHAGE; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; OBSERVATIONAL STUDY; OFF LABEL DRUG USE; OPERATING ROOM; OVERALL SURVIVAL; PRIORITY JOURNAL; SURVIVAL RATE; THROMBOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARDIAC SURGICAL PROCEDURES; CHEST TUBES; COAGULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION; FACTOR VIIA; FEMALE; HEMOSTASIS, SURGICAL; HUMANS; INTENSIVE CARE; MALE; MIDDLE AGED; OFF-LABEL USE; POSTOPERATIVE HEMORRHAGE; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; THROMBOSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 82655180882     PISSN: 10107940     EISSN: 1873734X     Source Type: Journal    
DOI: 10.1016/j.ejcts.2011.03.032     Document Type: Article

References (25)

1. Despotis G.J., Avidan M.S., Hogue C.W. Mechanisms and attenuation of hemostatic activation during extracorporeal circulation. Ann Thorac Surg 2001, 72:S1821-S1831.
2. Levy J.H. Pharmacologic preservation of the hemostatic system during cardiac surgery. Ann Thorac Surg 2001, 72:S1814-S1820.
3. Dacey L.J., Munoz J.J., Baribeau Y.R., Johnson E.R., Lahey S.J., Leavitt B.J., Quinn R.D., Nugent W.C., Birkmeyer J.D., O'Connor G.T. Reexploration for hemorrhage following coronary artery bypass grafting: incidence and risk factors. Northern New England Cardiovascular Disease Study Group. Arch Surg 1998, 133:442-447.
4. Moulton M.J., Creswell L.L., Mackey M.E., Cox J.L., Rosenbloom M. Reexploration for bleeding is a risk factor for adverse outcomes after cardiac operations. J Thorac Cardiovasc Surg 1996, 111:1037-1046.
5. Diprose P., Herbertson M.J., O'Shaughnessy D., Deakin C.D., Gill R.S. Reducing allogeneic transfusion in cardiac surgery: a randomized double-blind placebo-controlled trial of antifibrinolytic therapies used in addition to intra-operative cell salvage. Br J Anaesth 2005, 94:271-278.
6. Gill R., Herbertson M., Vuylsteke A., Olsen P.S., von Heymann C., Mythen M., Sellke F., Booth F., Schmidt T.A. Safety and efficacy of recombinant activated factor VII: a randomized placebo-controlled trial in the setting of bleeding after cardiac surgery. Circulation 2009, 120:21-27.
7. Warren O., Mandal K., Hadjianastassiou V., Knowlton L., Panesar S., John K., Darzi A., Athanasiou T. Recombinant activated factor VII in cardiac surgery: a systematic review. Ann Thorac Surg 2007, 83:707-714.
8. Aldouri M. The use of recombinant factor VIIa in controlling surgical bleeding in non-haemophiliac patients. Pathophysiol Haemost Thromb 2002, 32:41-46.
9. Karkouti K., Beattie W.S., Arellano R., Aye T., Bussieres J.S., Callum J.L., Cheng D., Heinrich L., Kent B., Lee T.W., MacAdams C., Mazer C.D., Muirhead B., Rochon A.G., Rubens F.D., Sawchuk C., Wang S., Waters T., Wong B.I., Yau T.M. Comprehensive Canadian review of the off-label use of recombinant activated factor VII in cardiac surgery. Circulation 2008, 118:331-338.
10. Masud F., Bostan F., Chi E., Pass S., Samir H., Stuebing K., Liebl M. Recombinant factor VIIa treatment of severe bleeding in cardiac surgery patients: a retrospective analysis of dosing, efficacy, and safety outcomes. J Cardiothorac Vasc Anesth 2009, 23:28-33.
11. Dunkley S., Phillips L., McCall P., Brereton J., Lindeman R., Jankelowitz G., Cameron P. Recombinant activated factor VII in cardiac surgery: experience from the Australian and New Zealand Haemostasis Registry. Ann Thorac Surg 2008, 85:836-844.
12. Vincent J.L., Rossaint R., Riou B., Ozier Y., Zideman D., Spahn D.R. Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding-a European perspective. Crit Care 2006, 10:R120.
13. Dunning J., Versteegh M., Fabbri A., Pavie A., Kohl P., Lockowandt U., Nashef S. Guideline on antiplatelet and anticoagulation management in cardiac surgery. Eur J Cardiothorac Surg 2008, 34:73-92. on behalf of the EACTS Audit, Guidelines Committee.
14. Bélisle S., Hardy J.F. Hemorrhage and the use of blood products after cardiac operations: myths and realities. Ann Thorac Surg 1996, 62:1908-1917.
15. Karkouti K., Beattie W., Wijeysundera D., Yau T., McCluskey S., Ghannam M., Sutton D., van Rensburg A., Karski J. Recombinant factor VIIa for intractable blood loss after cardiac surgery: a propensity score-matched case-control analysis. Transfusion 2005, 45:26-34.
16. Willis C., Bird R., Mullany D., Cameron P., Phillips L. Use of rFVIIa for critical bleeding in cardiac surgery: dose variation and patient outcomes. Vox Sang 2010, 98:531-537.
17. Karkouti K., Yau T., Riazi S., Dattilo K., Wasowicz M., Meineri M., McCluskey S., Wijeysundera D., van Rensburg A., Beattie W. Determinants of complications with recombinant factor VIIa for refractory blood loss in cardiac surgery. Can J Anesth 2006, 53:802-809.
18. O'Connell K., Wood J., Wise R., Lozier J., Braun M. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 2006, 295:293-298.
19. Roberts H.R. Recombinant factor VIIa (Novoseven) and the safety of treatment. Semin Hematol 2001, 38:48-50.
20. von Heymann C., Redlich U., Jain U., Kastrup M., Schroeder T., Sander M., Grosse J., Ziemer S., Koscielny J., Konertz W.F., Wernecke K.D., Spies C. Recombinant activated factor VII for refractory bleeding after cardiac surgery-a retrospective analysis of safety and efficacy. Crit Care Med 2005, 33:2241-2246.
21. Marik P., Andrews L., Maini B. The incidence of deep venous thrombosis in ICU patients. Chest 1997, 111:661-664.
22. Gandhi M.J., Pierce R.A., Zhang L., Moon M.R., Despotis G.J., Moazami N. Use of activated recombinant factor VII for severe coagulopathy post ventricular assist device or orthotopic heart transplant. J Cardiothorac Surg 2007, 2:32.
23. Bruckner B., DiBardino D., Ning Q., Adeboygeun A., Mahmoud K., Valdes J., Eze J., Allison P., Cooley D., Gregoric I., Frazier O. High incidence of thromboembolic events in left ventricular assist device patients treated with recombinant activated factor VII. J Heart Lung Transplant 2009, 28:785-790.
24. Rastan A.J., Lachmann N., Walther T., Doll N., Gradistanac T., Gommert J.F., Lehmann S., Wittekind C., Mohr F.W. Autopsy findings in patients on postcardiotomy extracorporeal membrane oxygenation (ECMO). Int J Artif Organs 2006, 29:1121-1131.
25. Schenk S., El-Banayosy A., Prohaska W., Arusoglu L., Morshuis M., Koester-Eiserfunke W., Kizner L., Murray E., Eichler P., Koerfer R., Greinacher A. Heparin-induced thrombocytopenia in patients receiving mechanical circulatory support. J Thorac Cardiovasc Surg 2006, 131:1373-1381.